Meso Numismatics Announces Cellgenic’s Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September
Meso Numismatics (MSSV), soon to be renamed Regenerative Medical Technology Group, announces Global Stem Cells Group's (GSCG) sponsorship of three major Regenerative Medicine events in Peru this September. These events include:
1. International Regenerative Medicine Conference by ISSCA (Sept 6-7)
2. AMDAL 2024 (Sept 14-15)
3. MDE24 International Congress of Medicine and Aesthetic Dermatology (Sept 20-21)
Cellgenic, a division of GSCG, will showcase its new line of peptides and advanced exosome products at these events. The company aims to introduce its pioneering exosome technology to medical professionals, highlighting the potential growth in the Latin American market for exosome-based treatments.
Meso Numismatics (MSSV), che presto sarà rinominata Regenerative Medical Technology Group, annuncia il patrocinio del Global Stem Cells Group (GSCG) per tre importanti eventi di Medicina Rigenerativa in Perù questo settembre. Questi eventi includono:
1. Conferenza Internazionale di Medicina Rigenerativa organizzata da ISSCA (6-7 settembre)
2. AMDAL 2024 (14-15 settembre)
3. Congresso Internazionale di Medicina e Dermatologia Estetica MDE24 (20-21 settembre)
Cellgenic, una divisione del GSCG, presenterà la sua nuova linea di peptidi e prodotti avanzati a base di esosomi in queste occasioni. L'azienda intende introdurre la sua tecnologia innovativa sugli esosomi ai professionisti medici, evidenziando il potenziale di crescita nel mercato latinoamericano per i trattamenti a base di esosomi.
Meso Numismatics (MSSV), que pronto será renombrada como Regenerative Medical Technology Group, anuncia el patrocinio del Global Stem Cells Group (GSCG) para tres importantes eventos de Medicina Regenerativa en Perú este septiembre. Estos eventos incluyen:
1. Conferencia Internacional de Medicina Regenerativa por ISSCA (6-7 de septiembre)
2. AMDAL 2024 (14-15 de septiembre)
3. Congreso Internacional de Medicina y Dermatología Estética MDE24 (20-21 de septiembre)
Cellgenic, una división de GSCG, presentará su nueva línea de péptidos y productos avanzados de exosomas en estos eventos. La empresa busca introducir su tecnología pionera en exosomas a los profesionales médicos, destacando el potencial de crecimiento en el mercado latinoamericano para tratamientos basados en exosomas.
메소 누미스매틱스(MSSV)는 곧 재생 의료 기술 그룹으로 이름이 변경될 예정이며, 이번 9월 페루에서 열릴 세 가지 주요 재생 의료 행사에 대한 글로벌 줄기 세포 그룹(GSCG)의 후원을 발표합니다. 이러한 행사에는 다음이 포함됩니다:
1. ISSCA 주관 국제 재생 의학 회의 (9월 6-7일)
2. AMDAL 2024 (9월 14-15일)
3. MDE24 국제 의학 및 미용 피부과 학술대회 (9월 20-21일)
GSCG의 한 부서인 Cellgenic은 이 행사에서 새로운 펩타이드 및 고급 엑소좀 제품 라인을 선보일 예정입니다. 회사는 의료 전문가에게 혁신적인 엑소좀 기술을 소개하고, 엑소좀 기반 치료에 대한 라틴 아메리카 시장의 성장 잠재력을 강조하는 것을 목표로 합니다.
Meso Numismatics (MSSV), qui sera bientôt renommée Regenerative Medical Technology Group, annonce le parrainage du Global Stem Cells Group (GSCG) pour trois grands événements de Médecine Régénérative au Pérou ce septembre. Ces événements comprennent :
1. Conférence Internationale de Médecine Régénérative par l'ISSCA (6-7 septembre)
2. AMDAL 2024 (14-15 septembre)
3. Congrès International de Médecine et de Dermatologie Esthétique MDE24 (20-21 septembre)
Cellgenic, une division du GSCG, présentera sa nouvelle gamme de peptides et de produits avancés à base d'exosomes lors de ces événements. L'entreprise vise à présenter sa technologie innovante des exosomes aux professionnels de santé, mettant en lumière le potentiel de croissance du marché latino-américain pour les traitements basés sur les exosomes.
Meso Numismatics (MSSV), das bald in Regenerative Medical Technology Group umbenannt wird, gibt das Sponsoring der Global Stem Cells Group (GSCG) für drei wichtige Veranstaltungen der regenerativen Medizin in Peru im September bekannt. Zu diesen Veranstaltungen gehören:
1. Internationale Konferenz für Regenerative Medizin von ISSCA (6.-7. September)
2. AMDAL 2024 (14.-15. September)
3. Internationaler Kongress für Medizin und Ästhetische Dermatologie MDE24 (20.-21. September)
Cellgenic, eine Abteilung von GSCG, wird auf diesen Veranstaltungen ihre neue Linie von Peptiden und fortschrittlichen Exosomenprodukten präsentieren. Das Unternehmen plant, Fachleuten im Gesundheitswesen seine bahnbrechende Exosomen-Technologie vorzustellen und das Wachstumspotenzial des lateinamerikanischen Marktes für exosomenbasierte Behandlungen hervorzuheben.
- Expansion of GSCG's presence in the Latin American market through event sponsorships
- Introduction of new peptide product line by Cellgenic
- Potential growth opportunities in the Latin American exosome treatment market
- None.
Regenerative Medical Technology Group, is pleased to announce Global Stem Cells Group's (GSCG) launch of Cellgenic's three prominent Regenerative Medicine Events in Peru this September.
LAS VEGAS, NV / ACCESSWIRE / September 9, 2024 / Meso Numismatics, Inc. ("Meso Numismatics" or the "Company") (MSSV), a renowned leader in regenerative medicine, and in the process with FINRA of a name change to Regenerative Medical Technology Group, is pleased to announce Global Stem Cells Group's (GSCG) launch of Cellgenic's three prominent Regenerative Medicine Events in Peru this September. Cellgenic, the division of GSCG that promotes and distributes innovative products and equipment for physicians in the field of regenerative medicine, has recently introduced its new line of peptides. The company will prominently feature its advanced exosome and peptide products at all new Global Events.
Company Logo
"The ISSCA Regenerative Medicine Conference in Lima has been an incredible opportunity to unite leading physicians and experts from around the globe to discuss cutting-edge advancements in cellular therapy and regenerative medicine," said Dave Christensen, CEO. "Peru has consistently been at the forefront of these innovations, and we are excited to continue expanding our presence in the country. Our mission remains to educate physicians in point-of-care regenerative medicine techniques and protocols, ensuring that patients benefit from the latest, most effective treatments. The success of this event has already set the stage for our next conference in mid-2025."
Event Details:
International Regenerative Medicine Conference by ISSCA - September 6-7, 2024: Taking place at the prestigious Hilton Hotel, this event, hosted by the International Society for Stem Cell Application (ISSCA), will gather leading experts from around the world to discuss the latest advancements in stem cell research and regenerative therapies.
AMDAL 2024 - September 14-15, 2024: Held at the Sol de Oro Hotel in Miraflores, AMDAL 2024 will focus on the latest innovations in dermatology and laser treatments. This event will bring together professionals from across the medical and aesthetic fields to explore cutting-edge technologies and practices.
MDE24 International Congress of Medicine and Aesthetic Dermatology - September 20-21, 2024: This event, set to take place at the ESAN Convention Center, will highlight groundbreaking developments in aesthetic dermatology and medical treatments, attracting participants from across the globe.
These events will feature a diverse lineup of international and local speakers, as well as participating doctors from Peru and neighboring regions. As a sponsor, Cellgenic will have a unique opportunity to introduce its pioneering exosome technology to the attending medical professionals, demonstrating why exosomes represent a promising and expanding market in Latin America.
"Cellgenic is honored to participate in these prestigious events, where we will showcase our latest innovations in regenerative medicine," said Benito Novas, Founder of Global Stem Cells Group. "We are particularly excited to introduce our exosome products to a new audience in this region. Additionally, we are leveraging these platforms to officially launch our new line of peptides, which we believe could offer significant benefits to medical professionals and patients alike."
Exosomes, derived from mesenchymal stem cells, have been increasingly recognized for their potential in enhancing regenerative processes, offering new avenues for treatment in areas such as aesthetic medicine, orthopedics, and chronic conditions. The Latin American market, with its growing focus on advanced medical therapies, might be poised for significant growth in the adoption of exosome-based treatments.
Global Stem Cells Group Remains a Leader in the Industry
Global Stem Cells Group's commitment to innovation and excellence sets it apart from the competition. By continually thinking in ways that others do not, GSCG remains a pioneering force in regenerative medicine. Its approach involves not only developing cutting-edge products but also fostering a collaborative environment with researchers, healthcare providers, and industry experts to ensure the highest standards of quality and efficacy. GSCG's comprehensive education and training programs further underscore their dedication to advancing the field, ensuring that medical professionals worldwide are well-equipped to utilize the latest regenerative therapies.
About Cellgenic
Cellgenic is a distinguished brand renowned for its cellular products and kits featuring the latest advancements in regenerative medicine, including Exosomes, Collagenase, PRP, Wharton's jelly mesenchymal cells, and now peptides. Committed to excellence in research and development, Cellgenic strives to provide healthcare professionals with cutting-edge technologies of the highest quality to enhance patient care and outcomes.
About Global Stem Cells Group
Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Meso Numismatic
Meso Numismatics Corp is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative patient therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare. The Company also distributes stem cells and other regenerative based cell lines, and equipment internationally and likewise specializes in education and training physicians in the area of regenerative medicine.
Please see this and other Company filings at www.sec.gov.
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Company herein, including those related to the opening of the Regenerative Medicine Clinic and Laboratory and its ability to expand into the UAE markets for regenerative care, are expressly qualified in their entirety by the above-mentioned cautionary statement. The Company disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
investor.relations@mssvinc.com
Telephone: (800) 956-3935
Contact Information
Investor Relations
Investor Relations
investor.relations@mssvinc.com
Related Video
https://www.youtube.com/watch?v=Xc3LYP-tl2A
SOURCE: Meso Numismatics, Inc.
View the original press release on accesswire.com
FAQ
What events is Meso Numismatics (MSSV) sponsoring in Peru in September 2024?
What new products will Cellgenic showcase at the Peru events in September 2024?
Why is Meso Numismatics (MSSV) focusing on the Latin American market for exosome treatments?
What is the new name Meso Numismatics (MSSV) is changing to?
